Statements (74)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Roxon_Energy_Corporation
|
| gptkbp:affiliation |
Various scientific organizations
|
| gptkbp:associatedWith |
gptkb:Spider-Man
|
| gptkbp:CEO |
gptkb:Norman_Osborn
|
| gptkbp:challenges |
Regulatory scrutiny
|
| gptkbp:collaborations |
Universities
|
| gptkbp:communityInvolvement |
Philanthropy
|
| gptkbp:competitors |
Alchemax
|
| gptkbp:employees |
Thousands
|
| gptkbp:famousFor |
Green Goblin serum
|
| gptkbp:foundedBy |
gptkb:Norman_Osborn
|
| gptkbp:headCoach |
gptkb:Dr._Curt_Connors
|
| gptkbp:headOfMarketing |
gptkb:Mary_Jane_Watson
|
| gptkbp:headquarters |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Oscorp Pharmaceuticals
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:innovation |
Biotechnology
|
| gptkbp:investmentFocus |
Advanced technology
|
| gptkbp:keyPeople |
gptkb:Harry_Osborn
|
| gptkbp:legalStatus |
Ethical violations
|
| gptkbp:market |
Global
|
| gptkbp:notableEvent |
Green Goblin transformation
|
| gptkbp:parentCompany |
gptkb:Oscorp_Industries
|
| gptkbp:partnerships |
Various biotech firms
|
| gptkbp:patentCitation |
Numerous
|
| gptkbp:philanthropy |
Health research funding
|
| gptkbp:productLine |
Medical devices
Clinical trials Personalized medicine Antibiotics Vaccines Diagnostics Consumer health products Cosmetic products Biologics Oncology drugs Dermatology products Combination therapies Immunotherapies Nutraceuticals Over-the-counter medications Cardiovascular drugs Research and development services Gene therapies Hormonal therapies Vaccination programs Diabetes medications Pain management drugs Cell therapies Surgical products Women's health products Travel health products Rare disease treatments Veterinary products Mental health medications Pediatric medications Neurology drugs Men's health products Chronic illness management drugs Geriatric medications Lifestyle drugs Transplantation drugs Orphan_drugs |
| gptkbp:products |
Genetic research
Pharmaceutical drugs |
| gptkbp:publicPerception |
Mixed
|
| gptkbp:reputation |
Controversial
|
| gptkbp:researchFocus |
Genetic engineering
|
| gptkbp:revenue |
Billions
|
| gptkbp:strategicGoals |
Market leadership
|
| gptkbp:subsidiary |
gptkb:Oscorp_Robotics
|
| gptkbp:sustainabilityPractices |
Limited
|
| gptkbp:technology |
Nanotechnology
|